What is the 13F Pro Quality Score for VOR?

13F Pro ranks Vor Biopharma Inc. (VOR) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View VOR's current score at https://13fpro.ai/research/VOR (free sign-up required for the full ranking).

Where does 13F Pro source VOR data?

All Vor Biopharma Inc. fundamentals and ownership data come directly from SEC EDGAR. Vor Biopharma Inc. files with the SEC under CIK 1817229. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is VOR in?

Vor Biopharma Inc. (VOR) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is VOR research updated on 13F Pro?

VOR's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Vor Biopharma Inc.(VOR)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1817229 VOR stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

VOR Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Vor Biopharma Inc. (VOR), a Healthcare sector company. VOR is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Vor Biopharma Inc. reports net income of $-219.6M, free cash flow of $-38.3M. Top institutional holders of VOR by reported 13-F value include TCG Crossover Management,, RA CAPITAL MANAGEMENT, L.P., FCPM III SERVICES B.V., based on the most recent SEC filings. VOR trades on the Nasdaq exchange and files with the SEC under CIK 1817229. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VOR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vor Biopharma Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-219.6M

Free Cash Flow

Q1 2026

$-38.3M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-655.7% YoY

$-696.0MFY 2025

FY20 $-43.3MFY21 $-68.9MFY22 $-92.1MFY25 $-696.0M

Operating Income

-297.8% YoY

$-371.6MFY 2025

FY20 $-43.4MFY21 $-69.0MFY22 $-93.4MFY25 $-371.6M

EPS (Diluted)

-2925.8% YoY

$-70.50FY 2025

FY20 —FY21 $-2.10FY22 $-2.33FY25 $-70.50

Total Assets

+55.0% YoY

$464.1MFY 2025

FY20 $75.9MFY21 $242.6MFY22 $299.4MFY25 $464.1M

Op. Cash Flow

-67.6% YoY

$-142.7MFY 2025

FY20 $-36.3MFY21 $-69.1MFY22 $-85.1MFY25 $-142.7M

Metric	FY 2025	FY 2022	FY 2021	FY 2020	FY 2019
Net Income	$-696.0M -655.7%	$-92.1M -33.7%	$-68.9M -59.0%	$-43.3M	—
Operating Income	$-371.6M -297.8%	$-93.4M -35.4%	$-69.0M -59.2%	$-43.4M	—
EPS (Diluted)	$-70.50 -2925.8%	$-2.33 -11.0%	$-2.10	—	—
Total Assets	$464.1M +55.0%	$299.4M +23.4%	$242.6M +219.6%	$75.9M	—
Operating Cash Flow	$-142.7M -67.6%	$-85.1M -23.1%	$-69.1M -90.5%	$-36.3M	—

AI Insight: VOR Financial Trends

Vor swung to a Q4 2025 net income gain of $1.7B, but underlying operations remain cash-negative and equity deteriorated sharply through 2025.

• Net income surged to $1.7B in Q4 2025 from prior-quarter loss of $813M, reversing Q2–Q3 2025 collapse.

• Operating income remained negative in all periods; Q4 2025 at $-36M shows no operational profitability.

• Operating cash flow deteriorated from $-22M in Q2 2024 to $-38M in Q1 2026, signaling persistent cash burn.

• Equity collapsed from $98M in Q2 2024 to negative $150M by Q1 2026, indicating shareholder value destruction.

⚠ Q4 2025 $1.7B net income gain is likely non-cash or one-time; operating loss of $36M contradicts earnings.

⚠ Negative equity persists into Q1 2026; company is technically insolvent on a book basis.

AI Insight: VOR Ratio Trends

Data insufficient to assess trends — only Q2 2024 through Q1 2025 show any metrics, all deeply negative profitability indicators.

• ROE deteriorated sharply from −113.5% in Q2 2024 to −196.7% in Q1 2025, signaling accelerating losses relative to equity.

• ROA declined from −78.6% in Q2 2024 to −95.0% in Q3 2024, indicating worsening asset utilization efficiency.

⚠ All profitability metrics missing from Q2 2025 onward; unclear if data gaps reflect operational silence or reporting delays.

⚠ No leverage, margin, or cash-generation metrics available to assess capital structure or path to profitability.

Get alerted when VOR's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Vor Biopharma Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of VOR

TCG Crossover Management, LLC
$96.5M5,673,078 sh
RA CAPITAL MANAGEMENT, L.P.
$96.4M5,404,998 sh
FCPM III SERVICES B.V.
$73.5M4,117,354 sh
VR Adviser, LLC
$54.3M3,041,719 sh
Frazier Life Sciences Management, L.P.
$45.4M2,543,939 sh
Caligan Partners LP
$34.3M1,925,066 sh
GREAT POINT PARTNERS LLC
$31.2M1,750,000 sh
Paradigm Biocapital Advisors LP
$31.2M1,750,000 sh
FMR LLC
$27.5M1,539,670 sh
VANGUARD CAPITAL MANAGEMENT LLC
$25.6M1,433,280 sh

Fund	Value	Shares
TCG Crossover Management, LLC	$96.5M	5,673,078
RA CAPITAL MANAGEMENT, L.P.	$96.4M	5,404,998
FCPM III SERVICES B.V.	$73.5M	4,117,354
VR Adviser, LLC	$54.3M	3,041,719
Frazier Life Sciences Management, L.P.	$45.4M	2,543,939
Caligan Partners LP	$34.3M	1,925,066
GREAT POINT PARTNERS LLC	$31.2M	1,750,000
Paradigm Biocapital Advisors LP	$31.2M	1,750,000
FMR LLC	$27.5M	1,539,670
VANGUARD CAPITAL MANAGEMENT LLC	$25.6M	1,433,280

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put VOR on your watchlist

Track score changes the day Vor Biopharma Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is VOR a good stock to buy?

13F Pro's AI-powered analysis of Vor Biopharma Inc. (VOR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VOR are available on the VOR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own VOR?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VOR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vor Biopharma Inc.'s investment landscape.